NASDAQ · Biotechnology

BMRN (BMRN) Stock

$60.00 -0.04% NASDAQ: BMRN Healthcare

Valuation

MetricValue
Price$60.00
Market Cap$11.60B
P/E Ratio41.31
P/B Ratio1.79
P/S Ratio3.42
EPS (TTM)$0.00
52-Week High$66.28
52-Week Low$49.26
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE4.48%
ROA4.49%
ROCE8.76%
Gross Margin16.55%
Operating Margin16.55%
Net Margin8.29%
Debt/Equity0.23
Current Ratio5.81

Annual Financials (USD)

Metric20212022202320242025
Revenue$1.8B$2.1B$2.4B$2.9B$3.2B
Operating Profit$-82.0M$161.0M$186.0M$484.0M$533.0M
Net Profit$-64.0M$142.0M$168.0M$427.0M$349.0M
EPS$-0.35$0.75$0.88$2.21$1.80
Op Margin-4.5%7.7%7.7%17.0%16.6%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$6.0B$6.4B$6.8B$7.0B$7.6B
Total Liabilities$1.7B$1.8B$1.9B$1.3B$1.5B
Cash$587.0M$725.0M$755.0M$943.0M$1.3B
Borrowings$1.1B$1.1B$1.1B$649.0M$643.0M

Latest News

BMRN: Lowering target price to $65.00 Argus Research · Jul 15, 2026 FDA Accepts BMRN's sNDA Seeking Full Approval for Voxzogo Zacks · Jul 14, 2026 BioMarin Pharmaceutical (BMRN) Following Its VOXZOGO FDA Filing And The Case For Undervaluation Simply Wall St. · Jul 13, 2026 1 of Wall Street’s Favorite Stocks with Competitive Advantages and 2 We Avoid StockStory · Jul 13, 2026 BioMarin Says FDA Accepts Filing for Voxzogo's Full Approval in Children With Achondroplasia MT Newswires · Jul 13, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$305.0M$176.0M$159.0M$573.0M$828.0M
Investing Cash Flow$-486.0M$-141.0M$-219.0M$39.0M$-517.0M
Financing Cash Flow$3.0M$-85.0M$-86.0M$-31.0M$-57.0M
Net Cash Flow$-62.0M$137.0M$31.0M$188.0M$369.0M
Free Cash Flow$185.0M$55.0M$52.0M$475.0M$725.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.73
EV / EBITDA16.42
FCF Yield6.91%
Quick Ratio4.20
Interest Coverage48.45
Return 1Y4.69%
Return 3Y-32.50%
Return 5Y-24.53%

Ownership

Insiders Held0.35%
Institutions Held102.43%
Institutions Float Held102.78%
Institutional HolderSharesReport Date
Blackrock Inc.19,818,3012026-03-31
Dodge & Cox Inc.14,561,7592026-03-31
Primecap Management Company14,194,0052026-03-31
Vanguard Capital Management LLC8,643,1642026-03-31
Vanguard Portfolio Management LLC8,298,4752026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ALGNAlign Technology, Inc. $169.29 +1.36% 27.86 $12.12B 0.00%
BBIOBridgeBio Pharma, Inc. $85.33 +1.56% -22.41 $16.71B 0.00%
EXELExelixis, Inc. $55.96 +0.27% 16.38 $14.07B 0.00%
HALO $81.48 -0.55% 23.58 $9.66B 0.00%
MDGL $512.06 +0.33% 37.12 $11.83B 0.00%

About BMRN

BMRN is led by CEO Alexander Hardy, employs 3,221 people, headquartered in San Rafael, US, publicly traded since 1999.

BMRN stock trades at $60.00 with a market capitalization of $11.60B. The stock is valued at a price-to-earnings (P/E) ratio of 41.31, price-to-book of 1.79, price-to-sales of 3.42. Over the past 52 weeks the stock has ranged between $49.26 and $66.28, and currently trades 9.5% below its 52-week high.

On profitability, BMRN generates a return on equity (ROE) of 4.48%, return on capital employed of 8.76%, an operating margin of 16.55%, a net profit margin of 8.29%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides